Tag: global non alcoholic steatohepatitis treatment market

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

Non-Alcoholic Steatohepatitis Treatment Market Size Outlook: How Quickly Will Revenue Expand Through 2030?

The non-alcoholic steatohepatitis treatment market size has experienced rapid growth in recent years. It is expected to increase from $3.57 billion in 2025 to $4.98 billion in 2026, achieving a compound annual growth rate (CAGR) of 39.6%. Historically, this expansion can be linked to the growing prevalence of obesity, an increase in type 2 diabetes incidence, high consumption of processed foods, inadequate awareness regarding liver health, and limited treatment options for early-stage nash.

The non-alcoholic steatohepatitis treatment market size is anticipated to experience substantial growth over the upcoming years, projected to reach $18.97 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 39.7%. This expansion during the forecast period is driven by factors such as advancements in precision medicine, the development of novel NASH drugs, the adoption of digital health monitoring tools, government initiatives aimed at liver disease prevention, and increasing investment in liver disease research. Significant trends during this period are expected to include personalized lifestyle and diet management, advancements in non-invasive diagnostics, widespread fatty liver disease awareness programs, home-based liver health monitoring, and the development of novel pharmacological agents.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=41689345&type=smp&name=Non-Alcoholic%20Steatohepatitis%20Treatment%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Non-Alcoholic Steatohepatitis Treatment Market Growth Momentum: What Factors Are Shaping Demand?

The increasing occurrence of insulin resistance has propelled the growth of the non-alcoholic steatohepatitis treatment market. Insulin resistance develops when muscles, fat, and liver cells do not adequately respond to insulin and struggle to absorb glucose from the blood, resulting in high blood sugar. These issues are linked to an unhealthy lifestyle, excessive sugar intake, and genetic predisposition. The prevalence of insulin resistance has expanded due to a rise in diabetes and other liver-related concerns, which are treated by non-alcoholic steatohepatitis treatment. For instance, in July 2025, PubMed, a US-based free biomedical literature database maintained by the U.S. National Library of Medicine, reported a significant increase in the prevalence rates of general obesity, abdominal obesity, severe obesity, and insulin resistance, with rates rising from 34.9% to 41.4%, 62.5% to 67.0%, 5.2% to 11.5%, and 22.5% to 30.2%, respectively. Therefore, the heightened prevalence of insulin resistance, driven by various liver and diabetes diseases, will stimulate the non-alcoholic steatohepatitis treatment market.

Non-Alcoholic Steatohepatitis Treatment Market Segment Landscape And Growth Outlook

The non-alcoholic steatohepatitis treatment market covered in this report is segmented –

1) By Drug Type: Vitamin E And Pioglitazone, Ocaliva, Elafibranor, Selonsertib And cenicriviroc, Obeticholic Acid, Other Drugs Types

2) By Test Type: Blood Tests, Liver Biopsy, Imaging Procedures

3) By End User: Hospital Pharmacies, Retail And Specialty Pharmacies, Other End Users

Subsegments:

1) By Vitamin E And Pioglitazone: Vitamin E Supplements, Pioglitazone-Based Formulations.

2) By Ocaliva: Ocaliva (Obeticholic Acid) For NASH

3) By Elafibranor: Elafibranor Monotherapy, Elafibranor Combination Therapy

4) By Selonsertib And Cenicriviroc: Selonsertib Formulations, Cenicriviroc Formulations

5) By Obeticholic Acid: Immediate-Release Obeticholic Acid, Extended-Release Obeticholic Acid

6) By Other Drug Types: Novel Agents In Clinical Trials, Combination Therapies

Non-Alcoholic Steatohepatitis Treatment Market Trends Redefining Industry Growth

Leading companies within the non-alcoholic steatohepatitis treatment market are innovating products such as endogenous hormones to capture larger customer bases, achieve greater sales, and elevate revenue. Endogenous hormones are organic substances produced internally by the body’s various glands, tissues, or organs, playing vital roles in regulating physiological functions. An example of this is from September 2023, when 89bio Inc., a US-based biotechnology firm, announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) for Pegozafermin to treat individuals diagnosed with nonalcoholic steatohepatitis (NASH). Pegozafermin is distinguished by its composition as an engineered glycoPEGylated analog of fibroblast growth factor 21. This specific formulation is currently being developed for addressing non-alcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). Pegozafermin’s unique aspect lies in its application of specialized glycoPEGylated technology, which ensures an extended half-life while retaining its full potency. This advanced methodology improves the product’s effectiveness in modulating key factors associated with lipid metabolism, NASH, and hypertriglyceridemia, including the reduction of triglycerides, glycemic control, steatosis, inflammation, and fibrosis.

Non-Alcoholic Steatohepatitis Treatment Market Competitive Landscape: Who Leads The Industry?

Major companies operating in the non-alcoholic steatohepatitis treatment market are AstraZeneca PLC, Galmed Pharmaceuticals Ltd., Genfit S.A., Zydus Cadila Healthcare Limited, Bristol-Myers Squibb Company, Gilead Sciences Inc., Novo Nordisk A/S, Inventiva Pharma SA, NGM Biopharmaceuticals Inc., Galectin Therapeutics Inc., Madrigal Pharmaceuticals Corporation, Intercept Pharmaceuticals Inc., Cirius Therapeutics Inc., Viking Therapeutics Inc., Eli Lilly and Company, Terns Pharmaceuticals Inc., AbbVie Inc., Johnson & Johnson Private Limited, Sanofi S.A., F. Hoffmann-La Roche Ltd., C.H. Boehringer Sohn AG & Co. KG

View The Full Non-Alcoholic Steatohepatitis Treatment Market Report:

https://thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-treatment-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Non-Alcoholic Steatohepatitis Treatment Market Largest Region: Which Geography Holds The Highest Market Share?

North America was the largest region in the non-alcoholic steatohepatitis treatment market share in 2025. The regions covered in the non-alcoholic steatohepatitis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Non-Alcoholic Steatohepatitis Treatment Market Growth From $4.98 Billion In 2026 To $18.97 Billion By 2030 At A CAGR Of 39.7%

The market for non-alcoholic steatohepatitis treatments has seen explosive expansion in recent years. Valued at $3.57 billion in 2025, it is projected to reach $4.98 billion by 2026, reflecting a compound annual growth rate (CAGR) of 39.6%. This historic growth has been driven by factors such as the growing prevalence of obesity, a rising number of type 2 diabetes cases, high intake of processed foods, insufficient awareness regarding liver health, and a scarcity of therapeutic options for early-stage NASH.

The non-alcoholic steatohepatitis treatment market is projected to experience substantial expansion in the coming years, with its value anticipated to reach $18.97 billion by 2030, representing a compound annual growth rate (CAGR) of 39.7%. This upward trajectory during the forecast period is largely driven by progress in precision medicine, the creation of innovative NASH therapies, the integration of digital health monitoring technologies, governmental efforts aimed at preventing liver disease, and heightened funding for liver disease research. Key developments shaping this period include a focus on tailored lifestyle and dietary plans, progress in non-invasive diagnostic techniques, initiatives to raise awareness about fatty liver disease, at-home liver health monitoring solutions, and the emergence of new pharmacological agents.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8595&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Non-Alcoholic Steatohepatitis Treatment Market Demand Drivers Creating New Revenue Opportunities

The rising prevalence of insulin resistance is a key driver behind the expansion of the non-alcoholic steatohepatitis treatment market. Insulin resistance is a condition where muscle, fat, and liver cells fail to respond appropriately to insulin, making it difficult for the body to absorb glucose from the bloodstream and often resulting in elevated blood sugar levels. This condition is frequently linked to factors such as poor lifestyle choices, excessive sugar intake, and genetic predisposition. Due to the growing incidence of diabetes and other liver-related disorders, the use of non-alcoholic steatohepatitis treatments has increased substantially to manage insulin resistance. For example, data from PubMed—a free biomedical literature database managed by the U.S. National Library of Medicine—released in July 2025 showed notable rises in the prevalence of general obesity (from 34.9% to 41.4%), abdominal obesity (from 62.5% to 67.0%), severe obesity (from 5.2% to 11.5%), and insulin resistance (from 22.5% to 30.2%). As a result, the growing frequency of insulin resistance, driven by rising rates of liver diseases and diabetes, is expected to propel the non-alcoholic steatohepatitis treatment market forward.

Non-Alcoholic Steatohepatitis Treatment Market Segment Performance And Strategic Opportunities

The non-alcoholic steatohepatitis treatment market covered in this report is segmented –

1) By Drug Type: Vitamin E And Pioglitazone, Ocaliva, Elafibranor, Selonsertib And cenicriviroc, Obeticholic Acid, Other Drugs Types

2) By Test Type: Blood Tests, Liver Biopsy, Imaging Procedures

3) By End User: Hospital Pharmacies, Retail And Specialty Pharmacies, Other End Users

Subsegments:

1) By Vitamin E And Pioglitazone: Vitamin E Supplements, Pioglitazone-Based Formulations.

2) By Ocaliva: Ocaliva (Obeticholic Acid) For NASH

3) By Elafibranor: Elafibranor Monotherapy, Elafibranor Combination Therapy

4) By Selonsertib And Cenicriviroc: Selonsertib Formulations, Cenicriviroc Formulations

5) By Obeticholic Acid: Immediate-Release Obeticholic Acid, Extended-Release Obeticholic Acid

6) By Other Drug Types: Novel Agents In Clinical Trials, Combination Therapies

Non-Alcoholic Steatohepatitis Treatment Market Trends Driving Strategic Industry Expansion

Key players in the non-alcoholic steatohepatitis treatment market are focusing on the creation of advanced solutions like endogenous hormones to attract a broader customer base, boost sales, and drive revenue growth. Endogenous hormones are naturally produced within the body by various glands, tissues, or organs and are essential for regulating physiological functions. For example, in September 2023, 89bio Inc., a biotechnology firm based in the United States, revealed that the U.S. Food and Drug Administration (FDA) had granted Breakthrough Therapy Designation (BTD) to Pegozafermin for patients with nonalcoholic steatohepatitis (NASH). Pegozafermin is a unique product, distinguished by its engineered glycoPEGylated analog of fibroblast growth factor 21. This specially designed formulation is being developed to treat non-alcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). Its distinctiveness lies in the application of a specialized glycoPEGylated technology, which provides an extended half-life while maintaining its effectiveness. This innovative method improves the product’s ability to influence critical factors associated with lipid metabolism, NASH, and hypertriglyceridemia, such as reducing triglycerides, controlling blood sugar, and addressing steatosis, inflammation, and fibrosis.

Non-Alcoholic Steatohepatitis Treatment Market Key Players: Which Companies Shape Industry Competition?

Major companies operating in the non-alcoholic steatohepatitis treatment market are AstraZeneca PLC, Galmed Pharmaceuticals Ltd., Genfit S.A., Zydus Cadila Healthcare Limited, Bristol-Myers Squibb Company, Gilead Sciences Inc., Novo Nordisk A/S, Inventiva Pharma SA, NGM Biopharmaceuticals Inc., Galectin Therapeutics Inc., Madrigal Pharmaceuticals Corporation, Intercept Pharmaceuticals Inc., Cirius Therapeutics Inc., Viking Therapeutics Inc., Eli Lilly and Company, Terns Pharmaceuticals Inc., AbbVie Inc., Johnson & Johnson Private Limited, Sanofi S.A., F. Hoffmann-La Roche Ltd., C.H. Boehringer Sohn AG & Co. KG

Access The Complete Non-Alcoholic Steatohepatitis Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-treatment-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Non-Alcoholic Steatohepatitis Treatment Market Largest Region By Revenue And Market Share

North America was the largest region in the non-alcoholic steatohepatitis treatment market share in 2025. The regions covered in the non-alcoholic steatohepatitis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Is The Non-Alcoholic Steatohepatitis Treatment Market’s Market Value Anticipated To Evolve From 2026 To 2030?

The non-alcoholic steatohepatitis treatment market size has expanded considerably in recent years. It is projected to increase from $3.57 billion in 2025 to $4.98 billion in 2026, at a compound annual growth rate (CAGR) of 39.6%. The market’s historical growth can be attributed to the rising prevalence of obesity, an increasing incidence of type 2 diabetes, high consumption of processed foods, a lack of awareness about liver health, and limited treatment options for early-stage nash.

The non-alcoholic steatohepatitis treatment market is anticipated to experience significant expansion in the upcoming years, projected to reach $18.97 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 39.7%. This considerable growth during the forecast period is attributed to several factors, including advancements in precision medicine, the development of novel NASH drugs, the increasing adoption of digital health monitoring tools, government initiatives aimed at preventing liver disease, and a surge in investment dedicated to liver disease research. Furthermore, prominent trends expected over the forecast period involve personalized lifestyle and diet management, innovations in non-invasive diagnostics, the implementation of fatty liver disease awareness programs, the rise of home-based liver health monitoring, and the ongoing development of novel pharmacological agents.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8595&type=smp

Which Strategic Drivers Are Supporting The Non-Alcoholic Steatohepatitis Treatment Market Development?

The escalating occurrence of insulin resistance is set to drive the non-alcoholic steatohepatitis treatment market. Insulin resistance arises when muscle, fat, and liver cells inadequately respond to insulin, impeding glucose absorption from the blood and resulting in elevated blood sugar levels. This condition is associated with poor lifestyle choices, excessive sugar intake, and genetic predispositions. The prevalence of insulin resistance has expanded considerably due to the rise in diabetes and other liver-related problems, both of which are addressed by non-alcoholic steatohepatitis treatment. For instance, in July 2025, PubMed, a US-based free biomedical literature database maintained by the U.S. National Library of Medicine, reported significant increases in prevalence rates: general obesity from 34.9% to 41.4%, abdominal obesity from 62.5% to 67.0%, severe obesity from 5.2% to 11.5%, and insulin resistance from 22.5% to 30.2%, respectively. Thus, the increasing prevalence of insulin resistance, stemming from numerous liver and diabetes diseases, will act as a key driver for the non-alcoholic steatohepatitis treatment market.

How Is The Non-Alcoholic Steatohepatitis Treatment Market Examined Through Segment Analysis?

The non-alcoholic steatohepatitis treatment market covered in this report is segmented –

1) By Drug Type: Vitamin E And Pioglitazone, Ocaliva, Elafibranor, Selonsertib And cenicriviroc, Obeticholic Acid, Other Drugs Types

2) By Test Type: Blood Tests, Liver Biopsy, Imaging Procedures

3) By End User: Hospital Pharmacies, Retail And Specialty Pharmacies, Other End Users

Subsegments:

1) By Vitamin E And Pioglitazone: Vitamin E Supplements, Pioglitazone-Based Formulations.

2) By Ocaliva: Ocaliva (Obeticholic Acid) For NASH

3) By Elafibranor: Elafibranor Monotherapy, Elafibranor Combination Therapy

4) By Selonsertib And Cenicriviroc: Selonsertib Formulations, Cenicriviroc Formulations

5) By Obeticholic Acid: Immediate-Release Obeticholic Acid, Extended-Release Obeticholic Acid

6) By Other Drug Types: Novel Agents In Clinical Trials, Combination Therapies

Which Trends Are Influencing The Direction Of The Non-Alcoholic Steatohepatitis Treatment Market?

Leading companies in the non-alcoholic steatohepatitis treatment market are creating innovative products, such as endogenous hormones, to cater to larger customer bases, boost sales, and increase revenue. Endogenous hormones are naturally occurring substances produced internally by various glands, tissues, or organs, and they play vital roles in regulating physiological processes. For instance, in September 2023, 89bio Inc., a US-based biotechnology company, announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) for Pegozafermin for individuals diagnosed with nonalcoholic steatohepatitis (NASH). Pegozafermin is notable as a distinctive product due to its engineered glycoPEGylated analog of fibroblast growth factor 21. This specifically designed formulation is under development for addressing non-alcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). What makes Pegozafermin unique is its utilization of a specialized glycoPEGylated technology, ensuring an extended half-life while preserving its potency. This innovative approach enhances the product’s effectiveness in modulating key factors related to lipid metabolism, NASH, and hypertriglyceridemia, including triglyceride reduction, glycemic control, steatosis, inflammation, and fibrosis.

Which Companies Are Engaged In The Non-Alcoholic Steatohepatitis Treatment Market Environment?

Major companies operating in the non-alcoholic steatohepatitis treatment market are AstraZeneca PLC, Galmed Pharmaceuticals Ltd., Genfit S.A., Zydus Cadila Healthcare Limited, Bristol-Myers Squibb Company, Gilead Sciences Inc., Novo Nordisk A/S, Inventiva Pharma SA, NGM Biopharmaceuticals Inc., Galectin Therapeutics Inc., Madrigal Pharmaceuticals Corporation, Intercept Pharmaceuticals Inc., Cirius Therapeutics Inc., Viking Therapeutics Inc., Eli Lilly and Company, Terns Pharmaceuticals Inc., AbbVie Inc., Johnson & Johnson Private Limited, Sanofi S.A., F. Hoffmann-La Roche Ltd., C.H. Boehringer Sohn AG & Co. KG

Access The Complete Non-Alcoholic Steatohepatitis Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-treatment-global-market-report

Which Geographic Region Represents The Largest Non-Alcoholic Steatohepatitis Treatment Market Share?

North America was the largest region in the non-alcoholic steatohepatitis treatment market share in 2025. The regions covered in the non-alcoholic steatohepatitis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Non-Alcoholic Steatohepatitis Treatment Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=8595&type=smp

Browse Through More Reports Similar to the Global Non-Alcoholic Steatohepatitis Treatment Market 2026, By The Business Research Company

Non Alcoholic Steatohepatitis Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-treatment-global-market-report

Non Alcoholic Steatohepatitis Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-treatment-global-market-report

Non Alcoholic Steatohepatitis Biomarkers Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-biomarkers-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Will The Market Value Of The Non-Alcoholic Steatohepatitis Treatment Market Progress Between 2026 And 2030?

The non-alcoholic steatohepatitis treatment market has seen rapid expansion in its size over recent years. It is anticipated to expand from $3.57 billion in 2025 to $4.98 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 39.6%. Factors contributing to this historical expansion include the escalating prevalence of obesity, a surge in the incidence of type 2 diabetes, considerable intake of processed foods, insufficient understanding of liver health, and constrained therapeutic choices for early-stage nash.

The non-alcoholic steatohepatitis treatment market is projected to experience rapid expansion over the coming years. This market is forecast to reach $18.97 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 39.7%. Factors contributing to this growth during the outlook period include progress in precision medicine, the creation of innovative NASH drugs, the uptake of digital health monitoring instruments, governmental efforts aimed at preventing liver disease, and rising investment in liver disease research. Key trends anticipated for this forecast timeframe encompass individualized lifestyle and diet management, innovations in non-invasive diagnostics, initiatives for fatty liver disease awareness, at-home liver health monitoring, and the evolution of new pharmacological agents.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8595&type=smp

What Key Factors Are Shaping The Non-Alcoholic Steatohepatitis Treatment Market Landscape?

The non-alcoholic steatohepatitis treatment market is experiencing growth driven by a rising occurrence of insulin resistance. Insulin resistance manifests when the body’s muscle, fat, and liver cells fail to react sufficiently to insulin, impeding the effortless uptake of glucose from the bloodstream, which leads to elevated blood sugar levels. Factors such as an unhealthy lifestyle, excessive sugar intake, and genetic predispositions are associated with its development. The incidence of insulin resistance has expanded considerably, attributable to a rise in diabetes and various liver conditions, both of which are addressed by non-alcoholic steatohepatitis treatment. For example, in July 2025, PubMed, a free biomedical literature database based in the US and maintained by the U.S. National Library of Medicine, indicated a significant increase in the prevalence rates of general obesity, abdominal obesity, severe obesity, and insulin resistance, with these rates rising from 34.9% to 41.4%, 62.5% to 67.0%, 5.2% to 11.5%, and 22.5% to 30.2%, respectively. Consequently, the growing prevalence of insulin resistance, stemming from numerous liver and diabetes diseases, is set to propel the non-alcoholic steatohepatitis treatment market.

How Is The Non-Alcoholic Steatohepatitis Treatment Market Categorized Across Its Segment Groups?

The non-alcoholic steatohepatitis treatment market covered in this report is segmented –

1) By Drug Type: Vitamin E And Pioglitazone, Ocaliva, Elafibranor, Selonsertib And cenicriviroc, Obeticholic Acid, Other Drugs Types

2) By Test Type: Blood Tests, Liver Biopsy, Imaging Procedures

3) By End User: Hospital Pharmacies, Retail And Specialty Pharmacies, Other End Users

Subsegments:

1) By Vitamin E And Pioglitazone: Vitamin E Supplements, Pioglitazone-Based Formulations.

2) By Ocaliva: Ocaliva (Obeticholic Acid) For NASH

3) By Elafibranor: Elafibranor Monotherapy, Elafibranor Combination Therapy

4) By Selonsertib And Cenicriviroc: Selonsertib Formulations, Cenicriviroc Formulations

5) By Obeticholic Acid: Immediate-Release Obeticholic Acid, Extended-Release Obeticholic Acid

6) By Other Drug Types: Novel Agents In Clinical Trials, Combination Therapies

What Market Trends Are Affecting The Non-Alcoholic Steatohepatitis Treatment Market?

Leading companies within the non-alcoholic steatohepatitis treatment market are actively developing innovative products, such as endogenous hormones, to cater to broader customer bases, boost sales, and increase revenue. Endogenous hormones are naturally occurring substances produced internally by various glands, tissues, or organs, playing vital roles in regulating physiological processes. For instance, in September 2023, 89bio Inc., a US-based biotechnology company, announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) for Pegozafermin for individuals diagnosed with nonalcoholic steatohepatitis (NASH). Pegozafermin is distinct given it is an engineered glycoPEGylated analog of fibroblast growth factor 21. This specifically designed formulation is currently under development to address non-alcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). Pegozafermin’s uniqueness lies in its use of specialized glycoPEGylated technology, which ensures an extended half-life while maintaining its potency. This innovative approach enhances the product’s effectiveness in modulating key factors associated with lipid metabolism, NASH, and hypertriglyceridemia, including triglyceride reduction, glycemic control, steatosis, inflammation, and fibrosis.

Which Firms Are Influencing Competition In The Non-Alcoholic Steatohepatitis Treatment Market?

Major companies operating in the non-alcoholic steatohepatitis treatment market are AstraZeneca PLC, Galmed Pharmaceuticals Ltd., Genfit S.A., Zydus Cadila Healthcare Limited, Bristol-Myers Squibb Company, Gilead Sciences Inc., Novo Nordisk A/S, Inventiva Pharma SA, NGM Biopharmaceuticals Inc., Galectin Therapeutics Inc., Madrigal Pharmaceuticals Corporation, Intercept Pharmaceuticals Inc., Cirius Therapeutics Inc., Viking Therapeutics Inc., Eli Lilly and Company, Terns Pharmaceuticals Inc., AbbVie Inc., Johnson & Johnson Private Limited, Sanofi S.A., F. Hoffmann-La Roche Ltd., C.H. Boehringer Sohn AG & Co. KG

Get The Full Non-Alcoholic Steatohepatitis Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-treatment-global-market-report

Which Region Represents The Largest Share Of The Non-Alcoholic Steatohepatitis Treatment Market?

North America was the largest region in the non-alcoholic steatohepatitis treatment market share in 2025. The regions covered in the non-alcoholic steatohepatitis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Non-Alcoholic Steatohepatitis Treatment Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-treatment-global-market-report

Browse Through More Reports Similar to the Global Non-Alcoholic Steatohepatitis Treatment Market 2026, By The Business Research Company

Non Alcoholic Steatohepatitis Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-treatment-global-market-report

Non Alcoholic Steatohepatitis Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-treatment-global-market-report

Non Alcoholic Steatohepatitis Biomarkers Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-biomarkers-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Increase Is Anticipated For The Non-Alcoholic Steatohepatitis Treatment Market Over The 2026–2030 Period?

The non-alcoholic steatohepatitis treatment market has experienced rapid expansion in its size over recent years. Projections indicate it will expand from $3.57 billion in 2025 to $4.98 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 39.6%. Factors contributing to its historical growth include the increasing prevalence of obesity, a rise in the incidence of type 2 diabetes, significant consumption of processed foods, insufficient awareness regarding liver health, and restricted treatment options available for early-stage nash.

The market for non-alcoholic steatohepatitis (NASH) treatment is anticipated to experience substantial growth over the next few years, projected to reach $18.97 billion by 2030 with a compound annual growth rate (CAGR) of 39.7%. This growth during the forecast period is fueled by advancements in precision medicine, the development of innovative NASH drugs, the adoption of digital health monitoring tools, government initiatives aimed at preventing liver disease, and increased investment in liver disease research. Key trends expected in this period include personalized lifestyle and diet management, progress in non-invasive diagnostic methods, programs to raise awareness about fatty liver disease, home-based liver health monitoring, and the creation of novel pharmacological agents.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8595&type=smp

What Drivers Are Expected To Influence The Non-Alcoholic Steatohepatitis Treatment Market During The Forecast Period?

The non-alcoholic steatohepatitis treatment market is experiencing growth due to an increased prevalence of insulin resistance. Insulin resistance arises when muscle, fat, and liver cells do not respond effectively to insulin, thereby impeding the easy absorption of glucose from the blood and resulting in high blood sugar. This condition is linked to unhealthy lifestyles, excessive sugar consumption, and genetic factors. The utilization of non-alcoholic steatohepatitis treatment has risen because of the increased incidence of insulin resistance, often stemming from elevated diabetes and other liver-related issues. For example, in July 2025, PubMed, a US-based free biomedical literature database maintained by the U.S. National Library of Medicine, reported that the prevalence rates of general obesity, abdominal obesity, severe obesity, and insulin resistance significantly increased, moving from 34.9% to 41.4%, 62.5% to 67.0%, 5.2% to 11.5%, and 22.5% to 30.2% respectively. Therefore, the expanding prevalence of insulin resistance, driven by various liver and diabetes diseases, is set to drive the non-alcoholic steatohepatitis treatment market.

How Is The Non-Alcoholic Steatohepatitis Treatment Market Segmented Across Key Categories?

The non-alcoholic steatohepatitis treatment market covered in this report is segmented –

1) By Drug Type: Vitamin E And Pioglitazone, Ocaliva, Elafibranor, Selonsertib And cenicriviroc, Obeticholic Acid, Other Drugs Types

2) By Test Type: Blood Tests, Liver Biopsy, Imaging Procedures

3) By End User: Hospital Pharmacies, Retail And Specialty Pharmacies, Other End Users

Subsegments:

1) By Vitamin E And Pioglitazone: Vitamin E Supplements, Pioglitazone-Based Formulations.

2) By Ocaliva: Ocaliva (Obeticholic Acid) For NASH

3) By Elafibranor: Elafibranor Monotherapy, Elafibranor Combination Therapy

4) By Selonsertib And Cenicriviroc: Selonsertib Formulations, Cenicriviroc Formulations

5) By Obeticholic Acid: Immediate-Release Obeticholic Acid, Extended-Release Obeticholic Acid

6) By Other Drug Types: Novel Agents In Clinical Trials, Combination Therapies

Which Upcoming Trends Are Expected To Influence The Non-Alcoholic Steatohepatitis Treatment Market?

Major companies within the non-alcoholic steatohepatitis treatment market are creating innovative offerings, such as endogenous hormones, to attract wider customer bases, increase sales, and boost revenue. Endogenous hormones are substances naturally produced within the body by various glands, tissues, or organs, playing vital roles in regulating physiological processes. For instance, in September 2023, 89bio Inc., a US-based biotechnology company, announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) for Pegozafermin for individuals diagnosed with nonalcoholic steatohepatitis (NASH). Pegozafermin is a distinct product due to its engineered glycoPEGylated analog of fibroblast growth factor 21. This specifically designed formulation is being developed to address non-alcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). Pegozafermin’s uniqueness stems from its use of specialized glycoPEGylated technology, which ensures an extended half-life while maintaining its potency. This innovative approach enhances the product’s effectiveness in modulating key factors associated with lipid metabolism, NASH, and hypertriglyceridemia, including triglyceride reduction, glycemic control, steatosis, inflammation, and fibrosis.

Who Are The Dominant Players Shaping The Non-Alcoholic Steatohepatitis Treatment Market Landscape?

Major companies operating in the non-alcoholic steatohepatitis treatment market are AstraZeneca PLC, Galmed Pharmaceuticals Ltd., Genfit S.A., Zydus Cadila Healthcare Limited, Bristol-Myers Squibb Company, Gilead Sciences Inc., Novo Nordisk A/S, Inventiva Pharma SA, NGM Biopharmaceuticals Inc., Galectin Therapeutics Inc., Madrigal Pharmaceuticals Corporation, Intercept Pharmaceuticals Inc., Cirius Therapeutics Inc., Viking Therapeutics Inc., Eli Lilly and Company, Terns Pharmaceuticals Inc., AbbVie Inc., Johnson & Johnson Private Limited, Sanofi S.A., F. Hoffmann-La Roche Ltd., C.H. Boehringer Sohn AG & Co. KG

Read the full non-alcoholic steatohepatitis treatment market report here:

https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-treatment-global-market-report

Which Region Is Forecast To Lead The Non-Alcoholic Steatohepatitis Treatment Market In Terms Of Market Size?

North America was the largest region in the non-alcoholic steatohepatitis treatment market share in 2025. The regions covered in the non-alcoholic steatohepatitis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Non-Alcoholic Steatohepatitis Treatment Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=8595&type=smp

Browse Through More Reports Similar to the Global Non-Alcoholic Steatohepatitis Treatment Market 2026, By The Business Research Company

Non Alcoholic Steatohepatitis Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-treatment-global-market-report

Non Alcoholic Steatohepatitis Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-treatment-global-market-report

Non Alcoholic Steatohepatitis Biomarkers Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-biomarkers-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the non-alcoholic steatohepatitis treatment market from 2026–2035 with trusted insights from The Business Research Company

How much is the Non-Alcoholic Steatohepatitis Treatment Market valued at in 2026, and what valuation is forecast for 2030?

The non-alcoholic steatohepatitis treatment market size has seen substantial growth in recent times. It is anticipated to expand from $3.57 billion in 2025 to $4.98 billion in 2026, achieving a compound annual growth rate (CAGR) of 39.6%. The historical rise in this market can be attributed to the increasing prevalence of obesity, a growing incidence of type 2 diabetes, elevated consumption of processed foods, insufficient awareness about liver health, and the limited availability of treatment options for early-stage NASH.

The market for non-alcoholic steatohepatitis treatment is projected to experience rapid expansion over the coming years. This market is anticipated to reach a valuation of $18.97 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 39.7%. Factors contributing to this growth during the forecast timeframe include progress in precision medicine, the creation of new NASH medications, wider use of digital health monitoring instruments, government efforts to prevent liver disease, and greater financial commitment to liver disease studies. Key trends expected during this period encompass individualized lifestyle and diet strategies, breakthroughs in non-invasive diagnostics, campaigns raising awareness about fatty liver disease, at-home liver health surveillance, and the development of new pharmacological treatments.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8595&type=smp

What Drivers Are Influencing The Growth Of The Non-Alcoholic Steatohepatitis Treatment Market?

The increasing occurrence of insulin resistance has been a significant driver for the non-alcoholic steatohepatitis treatment market’s future growth. Insulin resistance is a condition where muscle, fat, and liver cells fail to adequately respond to insulin, making it difficult for them to absorb glucose from the blood, thus leading to high blood sugar. This condition is frequently linked to an unhealthy lifestyle, excessive sugar consumption, and genetic factors. The incidence of insulin resistance has escalated due to the rising prevalence of diabetes and other liver-related issues, which often require non-alcoholic steatohepatitis treatment. For instance, in July 2025, PubMed, a US-based free biomedical literature database maintained by the U.S. National Library of Medicine, reported notable increases in the prevalence rates of general obesity, abdominal obesity, severe obesity, and insulin resistance. These rates rose from 34.9% to 41.4%, 62.5% to 67.0%, 5.2% to 11.5%, and 22.5% to 30.2%, respectively. Therefore, the heightened prevalence of insulin resistance, arising from numerous liver and diabetes diseases, is set to drive the non-alcoholic steatohepatitis treatment market.

What Segments Are Included Within The Non-Alcoholic Steatohepatitis Treatment Market?

The non-alcoholic steatohepatitis treatment market covered in this report is segmented –

1) By Drug Type: Vitamin E And Pioglitazone, Ocaliva, Elafibranor, Selonsertib And cenicriviroc, Obeticholic Acid, Other Drugs Types

2) By Test Type: Blood Tests, Liver Biopsy, Imaging Procedures

3) By End User: Hospital Pharmacies, Retail And Specialty Pharmacies, Other End Users

Subsegments:

1) By Vitamin E And Pioglitazone: Vitamin E Supplements, Pioglitazone-Based Formulations.

2) By Ocaliva: Ocaliva (Obeticholic Acid) For NASH

3) By Elafibranor: Elafibranor Monotherapy, Elafibranor Combination Therapy

4) By Selonsertib And Cenicriviroc: Selonsertib Formulations, Cenicriviroc Formulations

5) By Obeticholic Acid: Immediate-Release Obeticholic Acid, Extended-Release Obeticholic Acid

6) By Other Drug Types: Novel Agents In Clinical Trials, Combination Therapies

Which Innovation Trends Are Advancing Developments Within The Non-Alcoholic Steatohepatitis Treatment Market?

Leading companies in the non-alcoholic steatohepatitis treatment market are actively developing innovative solutions, such as endogenous hormones, to reach wider customer bases, increase sales, and boost revenue. Endogenous hormones are naturally occurring substances produced within the body by various glands, tissues, or organs, playing vital roles in regulating physiological processes. For instance, in September 2023, 89bio Inc., a US-based biotechnology company, announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) for Pegozafermin to individuals diagnosed with nonalcoholic steatohepatitis (NASH). Pegozafermin is distinguished by its engineered glycoPEGylated analog of fibroblast growth factor 21. This specific formulation is currently being developed for addressing non-alcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). Pegozafermin’s unique aspect lies in its use of specialized glycoPEGylated technology, which ensures an extended half-life while preserving its potency. This advanced approach enhances the product’s effectiveness in modulating key factors related to lipid metabolism, NASH, and hypertriglyceridemia, including triglyceride reduction, glycemic control, steatosis, inflammation, and fibrosis.

Who Are The Top-Performing Companies In The Non-Alcoholic Steatohepatitis Treatment Market In Recent Years?

Major companies operating in the non-alcoholic steatohepatitis treatment market are AstraZeneca PLC, Galmed Pharmaceuticals Ltd., Genfit S.A., Zydus Cadila Healthcare Limited, Bristol-Myers Squibb Company, Gilead Sciences Inc., Novo Nordisk A/S, Inventiva Pharma SA, NGM Biopharmaceuticals Inc., Galectin Therapeutics Inc., Madrigal Pharmaceuticals Corporation, Intercept Pharmaceuticals Inc., Cirius Therapeutics Inc., Viking Therapeutics Inc., Eli Lilly and Company, Terns Pharmaceuticals Inc., AbbVie Inc., Johnson & Johnson Private Limited, Sanofi S.A., F. Hoffmann-La Roche Ltd., C.H. Boehringer Sohn AG & Co. KG

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-treatment-global-market-report

Which Region Currently Holds The Largest Share Of The Non-Alcoholic Steatohepatitis Treatment Market?

North America was the largest region in the non-alcoholic steatohepatitis treatment market share in 2025. The regions covered in the non-alcoholic steatohepatitis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Non-Alcoholic Steatohepatitis Treatment Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=8595&type=smp

Browse Through More Reports Similar to the Global Non-Alcoholic Steatohepatitis Treatment Market 2026, By The Business Research Company

Non Alcoholic Steatohepatitis Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-treatment-global-market-report

Non Alcoholic Steatohepatitis Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-treatment-global-market-report

Non Alcoholic Steatohepatitis Biomarkers Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-biomarkers-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the non-alcoholic steatohepatitis treatment market from 2025–2034 with trusted insights from The Business Research Company

What Are The Future Growth Projections For The Non-Alcoholic Steatohepatitis Treatment Market Size?

The non-alcoholic steatohepatitis treatment market size has expanded significantly in recent years. It is projected to increase from $2.6 billion in 2024 to $3.57 billion in 2025, achieving a compound annual growth rate (CAGR) of 37.5%. The historical growth in this sector is attributable to factors including the rising prevalence of NASH, enhanced awareness and diagnosis, pervasive lifestyle changes and the obesity epidemic, continued clinical research, improvements in healthcare infrastructure and access, alongside strong regulatory support and ongoing clinical trials.

The non-alcoholic steatohepatitis treatment market is projected to experience substantial expansion in the coming years. This market is forecast to reach $13.57 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 39.6%. Key drivers for this growth during the projection period include progress in drug development, greater awareness of the disease, an increase in its prevalence and associated risk factors, and a move towards personalized medicine approaches. Noteworthy trends expected during the forecast period encompass a patient-focused approach, ongoing technological innovations, the development of targeted therapies, an evolving regulatory environment, and breakthroughs in research.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8595&type=smp

What Core Market Drivers Are Expanding The Non-Alcoholic Steatohepatitis Treatment Industry?

A growing incidence of insulin resistance is propelling the non-alcoholic steatohepatitis treatment market. Insulin resistance arises when muscle, fat, and liver cells do not adequately respond to insulin, preventing easy absorption of glucose from the blood and resulting in high blood sugar. This condition is linked to an unhealthy lifestyle, excessive sugar consumption, and genetics. The prevalence of insulin resistance has risen significantly due to increased diabetes and other liver-related issues, which are treated with non-alcoholic steatohepatitis treatment. For instance, in January 2022, a report from the International Diabetes Federation, a Belgium-based global diabetes community, stated that diabetes impacts 537 million individuals (20-79 years old), representing one in ten, and this figure is anticipated to climb to 643 million by 2030 and 783 million by 2045. Furthermore, in January 2024, the American Cancer Society, a US-based nonprofit cancer advocacy organization, projected new cases of liver cancer to reach 41,630 in 2024, up from 41,210 in 2023. Thus, the increased prevalence of insulin resistance, driven by various liver and diabetes diseases, will fuel the non-alcoholic steatohepatitis treatment market.

What Segment Insights Are Highlighted In The Non-Alcoholic Steatohepatitis Treatment Market Report?

The non-alcoholic steatohepatitis treatment market covered in this report is segmented –

1) By Drug Type: Vitamin E And Pioglitazone, Ocaliva, Elafibranor, Selonsertib And cenicriviroc, Obeticholic Acid, Other Drugs Types

2) By Test Type: Blood Tests, Liver Biopsy, Imaging Procedures

3) By End User: Hospital Pharmacies, Retail And Specialty Pharmacies, Other End Users

Subsegments:

1) By Vitamin E And Pioglitazone: Vitamin E Supplements, Pioglitazone-Based Formulations.

2) By Ocaliva: Ocaliva (Obeticholic Acid) For NASH

3) By Elafibranor: Elafibranor-Based Treatments

4) By Selonsertib And Cenicriviroc: Selonsertib Formulations, Cenicriviroc Formulations

5) By Obeticholic Acid: Other Formulations Of Obeticholic Acid

6) By Other Drug Types: Novel Agents In Clinical Trials, Combination Therapies

Which Notable Trends Are Transforming The Non-Alcoholic Steatohepatitis Treatment Market Outlook?

The progress in developing non-alcoholic steatohepatitis (NASH) drugs represents a key trend growing in prominence within the non-alcoholic steatohepatitis treatment market. Many corporations are allocating resources to formulate innovative medications for liver conditions that possess reduced adverse effects. For example, in May 2022, Pfizer Inc., an American pharmaceutical and biotechnology enterprise, secured a fast-track designation from the U.S. Food and Drug Administration (FDA). This designation aims to accelerate the creation of their non-alcoholic steatohepatitis (NASH) drugs, namely ervogastat and clesacostat. Fast Track is a procedure designed to support Pfizer’s investigative combination therapy for addressing non-alcoholic steatohepatitis (NASH) with liver fibrosis, referred to as ervogastat (PF-06865571, a diacylglycerol O-acyltransferase 2 inhibitor, or DGAT2i) and clesacostat (PF-05221304, an acetyl-CoA carboxylase inhibitor, or ACCi).

Which Firms Are Driving Innovation Within The Non-Alcoholic Steatohepatitis Treatment Market?

Major companies operating in the non-alcoholic steatohepatitis treatment market are AstraZeneca PLC, Galmed Pharmaceuticals Ltd., Genfit S.A., Zydus Cadila Healthcare Limited, Bristol-Myers Squibb Company, Gilead Sciences Inc., Novo Nordisk A/S, Immuron Ltd., Inventiva Pharma SA, NGM Biopharmaceuticals Inc., Galectin Therapeutics Inc., Madrigal Pharmaceuticals Corporation, Intercept Pharmaceuticals Inc., Cirius Therapeutics Inc., Viking Therapeutics Inc., Eli Lilly and Company, Terns Pharmaceuticals Inc., Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Johnson & Johnson Private Limited, Sanofi S.A., F. Hoffmann-La Roche Ltd., C.H. Boehringer Sohn AG & Co. KG

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-treatment-global-market-report

What Regional Trends Are Shaping Growth In The Non-Alcoholic Steatohepatitis Treatment Market?

North America was the largest region in the non-alcoholic steatohepatitis treatment market share in 2024. The regions covered in the non-alcoholic steatohepatitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=8595&type=smp

Browse Through More Reports Similar to the Global Non-Alcoholic Steatohepatitis Treatment Market 2025, By The Business Research Company

Nutritional Analysis Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/nutritional-analysis-global-market-report

Probiotics Dietary Supplements Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/probiotics-dietary-supplements-global-market-report

Protein Supplements Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/protein-supplements-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the non-alcoholic steatohepatitis treatment market from 2025–2034 with trusted insights from The Business Research Company

What Are The Future Growth Projections For The Non-Alcoholic Steatohepatitis Treatment Market Size?

The non-alcoholic steatohepatitis treatment market size has expanded significantly in recent years. It is projected to increase from $2.6 billion in 2024 to $3.57 billion in 2025, achieving a compound annual growth rate (CAGR) of 37.5%. The historical growth in this sector is attributable to factors including the rising prevalence of NASH, enhanced awareness and diagnosis, pervasive lifestyle changes and the obesity epidemic, continued clinical research, improvements in healthcare infrastructure and access, alongside strong regulatory support and ongoing clinical trials.

The non-alcoholic steatohepatitis treatment market is projected to experience substantial expansion in the coming years. This market is forecast to reach $13.57 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 39.6%. Key drivers for this growth during the projection period include progress in drug development, greater awareness of the disease, an increase in its prevalence and associated risk factors, and a move towards personalized medicine approaches. Noteworthy trends expected during the forecast period encompass a patient-focused approach, ongoing technological innovations, the development of targeted therapies, an evolving regulatory environment, and breakthroughs in research.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8595&type=smp

What Core Market Drivers Are Expanding The Non-Alcoholic Steatohepatitis Treatment Industry?

A growing incidence of insulin resistance is propelling the non-alcoholic steatohepatitis treatment market. Insulin resistance arises when muscle, fat, and liver cells do not adequately respond to insulin, preventing easy absorption of glucose from the blood and resulting in high blood sugar. This condition is linked to an unhealthy lifestyle, excessive sugar consumption, and genetics. The prevalence of insulin resistance has risen significantly due to increased diabetes and other liver-related issues, which are treated with non-alcoholic steatohepatitis treatment. For instance, in January 2022, a report from the International Diabetes Federation, a Belgium-based global diabetes community, stated that diabetes impacts 537 million individuals (20-79 years old), representing one in ten, and this figure is anticipated to climb to 643 million by 2030 and 783 million by 2045. Furthermore, in January 2024, the American Cancer Society, a US-based nonprofit cancer advocacy organization, projected new cases of liver cancer to reach 41,630 in 2024, up from 41,210 in 2023. Thus, the increased prevalence of insulin resistance, driven by various liver and diabetes diseases, will fuel the non-alcoholic steatohepatitis treatment market.

What Segment Insights Are Highlighted In The Non-Alcoholic Steatohepatitis Treatment Market Report?

The non-alcoholic steatohepatitis treatment market covered in this report is segmented –

1) By Drug Type: Vitamin E And Pioglitazone, Ocaliva, Elafibranor, Selonsertib And cenicriviroc, Obeticholic Acid, Other Drugs Types

2) By Test Type: Blood Tests, Liver Biopsy, Imaging Procedures

3) By End User: Hospital Pharmacies, Retail And Specialty Pharmacies, Other End Users

Subsegments:

1) By Vitamin E And Pioglitazone: Vitamin E Supplements, Pioglitazone-Based Formulations.

2) By Ocaliva: Ocaliva (Obeticholic Acid) For NASH

3) By Elafibranor: Elafibranor-Based Treatments

4) By Selonsertib And Cenicriviroc: Selonsertib Formulations, Cenicriviroc Formulations

5) By Obeticholic Acid: Other Formulations Of Obeticholic Acid

6) By Other Drug Types: Novel Agents In Clinical Trials, Combination Therapies

Which Notable Trends Are Transforming The Non-Alcoholic Steatohepatitis Treatment Market Outlook?

The progress in developing non-alcoholic steatohepatitis (NASH) drugs represents a key trend growing in prominence within the non-alcoholic steatohepatitis treatment market. Many corporations are allocating resources to formulate innovative medications for liver conditions that possess reduced adverse effects. For example, in May 2022, Pfizer Inc., an American pharmaceutical and biotechnology enterprise, secured a fast-track designation from the U.S. Food and Drug Administration (FDA). This designation aims to accelerate the creation of their non-alcoholic steatohepatitis (NASH) drugs, namely ervogastat and clesacostat. Fast Track is a procedure designed to support Pfizer’s investigative combination therapy for addressing non-alcoholic steatohepatitis (NASH) with liver fibrosis, referred to as ervogastat (PF-06865571, a diacylglycerol O-acyltransferase 2 inhibitor, or DGAT2i) and clesacostat (PF-05221304, an acetyl-CoA carboxylase inhibitor, or ACCi).

Which Firms Are Driving Innovation Within The Non-Alcoholic Steatohepatitis Treatment Market?

Major companies operating in the non-alcoholic steatohepatitis treatment market are AstraZeneca PLC, Galmed Pharmaceuticals Ltd., Genfit S.A., Zydus Cadila Healthcare Limited, Bristol-Myers Squibb Company, Gilead Sciences Inc., Novo Nordisk A/S, Immuron Ltd., Inventiva Pharma SA, NGM Biopharmaceuticals Inc., Galectin Therapeutics Inc., Madrigal Pharmaceuticals Corporation, Intercept Pharmaceuticals Inc., Cirius Therapeutics Inc., Viking Therapeutics Inc., Eli Lilly and Company, Terns Pharmaceuticals Inc., Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Johnson & Johnson Private Limited, Sanofi S.A., F. Hoffmann-La Roche Ltd., C.H. Boehringer Sohn AG & Co. KG

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-treatment-global-market-report

What Regional Trends Are Shaping Growth In The Non-Alcoholic Steatohepatitis Treatment Market?

North America was the largest region in the non-alcoholic steatohepatitis treatment market share in 2024. The regions covered in the non-alcoholic steatohepatitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=8595&type=smp

Browse Through More Reports Similar to the Global Non-Alcoholic Steatohepatitis Treatment Market 2025, By The Business Research Company

Nutritional Analysis Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/nutritional-analysis-global-market-report

Probiotics Dietary Supplements Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/probiotics-dietary-supplements-global-market-report

Protein Supplements Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/protein-supplements-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model